The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Platinum vs non-platinum chemotherapy for platinum-resistant ovarian cancer: A meta-analysis.
 
Alexey Rumyantsev
Stock and Other Ownership Interests - MSD; Novartis; Pfizer
Honoraria - AstraZeneca/MedImmune; BIOCAD; Eisai; MSD
 
Alexandra Tyulyandina
Stock and Other Ownership Interests - Ruspharmtech (I)
Honoraria - AstraZeneca/MedImmune; BioCad; Eisai; MSD Oncology; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Eisai; MSD Oncology
Research Funding - AstraZeneca/MedImmune; biocad; MSD Oncology
 
Mikhail Fedyanin
No Relationships to Disclose
 
Ilya Pokataev
No Relationships to Disclose
 
Elena Glazkova
Stock and Other Ownership Interests - MSD; Pfizer
Honoraria - Eisai; Novartis; Pfizer
 
Edgar Israelyan
No Relationships to Disclose
 
Sergei Tjulandin
Stock and Other Ownership Interests - RosPharmTech
Consulting or Advisory Role - AstraZeneca; BioCad; Lilly; Novartis; Roche
Speakers' Bureau - AstraZeneca; Merck Sharp & Dohme; Novartis; Pierre Fabre; R-Pharm; Roche
Research Funding - Abbvie (Inst); Bristol Myers Squibb Foundation (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); SERVIER